Compare OLMA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLMA | MDXG |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2020 | 2007 |
| Metric | OLMA | MDXG |
|---|---|---|
| Price | $15.39 | $3.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $44.89 | $10.00 |
| AVG Volume (30 Days) | ★ 1.7M | 781.2K |
| Earning Date | 03-16-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.00 | 14.29 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $347.47 | $13.02 |
| P/E Ratio | ★ N/A | $12.34 |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $2.86 | $3.77 |
| 52 Week High | $36.26 | $7.99 |
| Indicator | OLMA | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 39.54 | 28.94 |
| Support Level | $13.11 | N/A |
| Resistance Level | $27.38 | $7.39 |
| Average True Range (ATR) | 0.99 | 0.15 |
| MACD | 0.30 | -0.00 |
| Stochastic Oscillator | 57.80 | 23.33 |
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.